How has Xeris Biopharma Holdings, Inc.'s net investment in lease changed year-over-year?

Xeris Biopharma Holdings, Inc.'s net investment in lease decreased by 2.6% year-over-year, from $22.53M to $21.95M.

Xeris Biopharma Holdings, Inc. XERS Net Investment in Lease

Net Investment in Lease at other companies

Corcept TherapeuticsCORT

——

Eton Pharmaceuticals, Inc.ETON

——

Zevra Therapeutics, Inc.ZVRA

——

Crinetics PharmaceuticalsCRNX

——

Catalyst PharmaceuticalCPRX

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$83.1M+38.3%

Gross profit$72.6M+41.2%

Operating income$7.9M+356%

Net income$2.2M+124%

EPS (diluted)$0.01+117%

Balance sheet

See full

Cash & equivalents$111.8M+91.2%

Total debt$258.6M-3.8%

Total equity$13.0M+137%

Total assets$392.0M+24.3%

Cash flow

See full

Operating cash flow$9.9M+198%

CapEx$131.0K—

Free cash flow-$29.1M—

Valuation

See full

Market cap$1.28B+76.9%

Enterprise value$1.42B+52.7%

P/E106.4×—

P/S4.1×+0.8×

Profitability

See full

Gross margin85.9%+3.7pp

Operating margin11.4%+7.7pp

Net margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-209.8%—

Debt / equity19.9×—

Current ratio2.1×+0.4×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s net investment in lease?: Xeris Biopharma Holdings, Inc. (XERS) reported net investment in lease of $21.95M in Q1 2026.
How has Xeris Biopharma Holdings, Inc.'s net investment in lease changed year-over-year?: Xeris Biopharma Holdings, Inc.'s net investment in lease decreased by 2.6% year-over-year, from $22.53M to $21.95M.